Analyst Ratings For NASDAQ:SRNE – Sorrento Therapeutics (NASDAQ:SRNE)
.
Some recent analyst ratings include
- 1/19/2018-Oppenheimer Reiterated Rating of Buy.
- 8/3/2017-Roth Capital initiated coverage with a Buy rating.
- 8/3/2017-UBS Group initiated coverage with a Outperform rating.
- 6/17/2017-FBR & Co Reiterated Rating of Buy.
- 8/12/2016-Brean Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:SRNE – Sorrento Therapeutics (NASDAQ:SRNE)
NASDAQ:SRNE – Sorrento Therapeutics (NASDAQ:SRNE) has insider ownership of 5.00% and institutional ownership of 25.02%.
- On 2/28/2018 George K Ng, Insider, bought 90,000 with an average share price of $9.95 per share and the total transaction amounting to $895,500.00.
- On 2/7/2018 Abg Management Ltd, Major Shareholder, sold 150,000 with an average share price of $7.19 per share and the total transaction amounting to $1,078,500.00.
- On 2/5/2018 Abg Management Ltd, Major Shareholder, sold 70,721 with an average share price of $8.00 per share and the total transaction amounting to $565,768.00.
- On 1/30/2018 Abg Management Ltd, Major Shareholder, sold 310,000 with an average share price of $7.64 per share and the total transaction amounting to $2,368,400.00.
- On 1/24/2018 Pacific Medtech (Bvi) Ltd Asia, Major Shareholder, sold 684,288 with an average share price of $7.56 per share and the total transaction amounting to $5,173,217.28.
- On 6/15/2017 Henry Ji, Insider, bought 29,001 with an average share price of $1.81 per share and the total transaction amounting to $52,491.81.
- On 6/15/2017 Jaisim Shah, Director, bought 10,002 with an average share price of $1.79 per share and the total transaction amounting to $17,903.58.
Recent Trading Activity for NASDAQ:SRNE – Sorrento Therapeutics (NASDAQ:SRNE)
Shares of NASDAQ:SRNE – Sorrento Therapeutics closed the previous trading session at 7.38 down -0.07 0.99% with 7.489999771118164 shares trading hands.